A Needle-Free EpiPen Alternative Exists. Your Insurance Probably Won't Cover It.
The FDA approved a needle-free alternative to the EpiPen over a year ago. But CVS Caremark just punted its formulary decision again, leaving millions of allergy patients stuck navigating a maze of prior authorizations and denials for a nasal spray that could save their lives.
Imagine you're a parent. Your kid has a severe peanut allergy. You've been carrying an EpiPen everywhere for years, dreading the day you might actually have to stab a needle into your child's thigh during a full-blown allergic emergency. Then the FDA approves a nasal spray that does the same thing. No needle. Just a spritz up the nose.
You'd want that, right? So would millions of other people.
There's just one problem. The company that decides which drugs your insurance actually pays for doesn't seem to be in any hurry to let you have it.
The Spray That Could Replace the EpiPen
Neffy, made by ARS Pharmaceuticals (ticker: SPRY), is the first FDA-approved needle-free epinephrine product for treating anaphylaxis. It's a nasal spray. You point it at a nostril and press. That's it. No uncapping, no jabbing, no worrying about whether you're doing it right while your kid's throat is swelling shut.
The FDA approved the adult version in 2024 and extended it to children in early 2025. Approval was based on four clinical studies in 175 adults showing that neffy delivers epinephrine into the bloodstream at levels comparable to EpiPen and standard intramuscular injection. Blood pressure and heart rate responses looked similar too. In a small pediatric study during actual allergic reactions, 100% of children responded to a single dose, with a median time to complete symptom resolution of 16 minutes.
This isn't some experimental moonshot. It's an approved, commercially available product solving a real problem: people who freeze up when they need to use a needle in an emergency. Studies consistently show that patients and caregivers delay or skip epinephrine injections out of fear. Neffy was supposed to fix that.
The Gatekeeper Said "Not Yet"
CVS Caremark is one of the largest pharmacy benefit managers (PBMs) in the country. PBMs are the middlemen who negotiate drug prices and decide which medications land on your insurance plan's approved list, called a formulary. If your drug isn't on the formulary, you're either paying full price, filing mountains of paperwork for a special exception, or just not getting it.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
ARS Pharmaceuticals submitted a proposal to CVS Caremark to add neffy to its commercial formulary without prior authorization, targeting a July 1, 2026 effective date. The company told investors the proposal was "in the final stages" of CVS's approval process.
Then July 1 came and went. No new commercial formulary additions materialized. ARS reported that payer talks were continuing, but the anticipated step-function improvement in access simply didn't happen. The next realistic window? The January 2027 formulary cycle.
This matters because CVS Caremark controls a significant share of U.S. commercial lives. Add Aetna, and you're looking at a large segment of commercially insured Americans locked out of easy neffy access.
The Coverage Map Is a Mess
To be fair, neffy isn't completely invisible to insurers. ARS claims 93% of commercial lives are technically "covered." But that number is misleading in the way that saying a restaurant "has food" is technically true even when everything on the menu requires a 45-minute wait.
Only 57% of covered lives can get neffy without prior authorization. The rest face step therapy (try a generic auto-injector first and "fail" it), restrictive criteria, or outright denials.
Express Scripts and OptumRx have been relatively friendly, offering unrestricted access. But a February 2025 analysis found that roughly 52% of commercially insured patients were under plans that effectively blocked or severely restricted neffy. The list of holdouts reads like a who's who of American health insurance: CVS Caremark, UnitedHealthcare, Aetna, multiple Blue Cross Blue Shield plans, and Prime Therapeutics.
Some plans have gone further. Kaiser Permanente Northwest requires that the prescriber be an allergist and that the patient demonstrate an inability to use an auto-injector. That's more restrictive than the FDA label itself.
Why PBMs Play Hard to Get
The economics here aren't complicated. Generic epinephrine auto-injectors are cheap. Neffy is a branded product. PBMs have strong financial incentives to steer patients toward the lowest-cost option, even when a clinically differentiated alternative exists.
Think of it like your cable company "offering" fiber internet but requiring you to prove your current copper connection literally doesn't work before they'll upgrade you. The better product exists. The infrastructure is there. But the gatekeeper profits from keeping you on the old plan.
ARS has disclosed that its gross-to-net revenue retention (the share of list price the company actually keeps after rebates and discounts) is about 52%. That means ARS is already giving away nearly half the sticker price to get on formularies. Even with those concessions, major PBMs are dragging their feet.
The Food Allergy Community Is Not Happy
Patient advocacy groups have started drawing battle lines. SnackSafely, a prominent food allergy advocacy outlet, has called out CVS Caremark by name, urging patients and caregivers to contact their insurers and push employer benefits departments to demand neffy coverage. The language is pointed: they describe the delay as "bureaucratic processes" rather than any medical rationale and say it's addressable through "substantial public pressure."
There's precedent for this kind of campaign working. In 2022, CVS Caremark tried to switch patients off the blood thinner Eliquis for non-medical reasons. A coordinated backlash from patient groups, physicians, and medical societies forced a full policy reversal within six months. Advocates are now explicitly citing that playbook.
The FTC is also investigating PBM practices broadly, examining how rebates and fees shape formulary decisions and whether patients are being forced to switch drugs for purely financial reasons. Neffy's situation fits that pattern perfectly.
Meanwhile, the Business Keeps Growing (Slowly)
Despite the access headaches, neffy is selling. Q1 2026 brought in $17.5 million in U.S. sales, roughly triple the prescription volume from a year earlier.
But the company is burning cash fast. ARS reported a net loss of $60.6 million in Q1 2026 alone, driven by heavy spending on direct-to-consumer advertising and sales infrastructure. The stock has been stuck in the high single digits, trading around $8.54 as of late June 2026.
The global epinephrine auto-injector market is worth roughly $2.2 to $3.5 billion in 2025, growing at a high-single-digit clip. Neffy's current share is tiny. But analysts view it as additive to the market rather than cannibalistic; it pulls in patients who avoided carrying epinephrine altogether because they feared needles.
What Happens Next
The CVS Caremark decision is the single biggest remaining U.S. payer catalyst for neffy. If it lands in the January 2027 formulary cycle, it could unlock a meaningful jump in prescriptions and revenue. If it slips again, the narrative shifts from "growing pains" to "structural access problem."
For patients, the workaround options are limited but real: ARS offers copay assistance that can bring costs down to $25 for many insured patients, and a capped cash price of $199 at participating pharmacies if insurance won't budge. A patient assistance program covers some uninsured individuals at no cost.
But $199 out of pocket for a drug your insurance should cover? For something your kid might need to survive an allergic reaction? That's not a solution. That's a symptom of a system where the middlemen have more power than the medicine.
4 min read
Lantheus Had the Data. The Factory Broke the Dream.
Lantheus' cancer imaging agent had flawless clinical data and a clean safety profile. The FDA rejected it anyway, and the reason has nothing to do with science. It's a cautionary tale about the hidden risk that keeps torpedoing biotech approvals.
